The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Interim report January – March 2024
The Group in summary 01/01/24 01/01/23 01/01/23 -31/03/24 -31/03/23 -31/12/23 Net sales 2 394 1 483 8 015 Operating result -17 979 -17 441 -93 579 Result after financial items -17 389 -17 476...Notice of Annual General Meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 15 May 2024 at 1.00 p.m. at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. The Board of Directors has...Intervacc publishes the 2023 Annual Report
Stockholm, April 10, 2024 – Intervacc AB (publ) announces that the company’s 2023 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the...Intervacc announces changes in the Nomination Committee
Stockholm, March 4, 2024 – The composition of the Nomination Committee in Intervacc AB (publ) (“Intervacc”) was announced in a Press Release on October 30, 2023. Due to the fact that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by...Jonas Sohlman appointed as new CEO for Intervacc
Stockholm, February 28, 2024 – The Board of Directors for Intervacc AB (publ) announces that acting CEO Jonas Sohlman has been appointed as the new CEO of Intervacc AB and assumes the position immediately. The recruitment process that the previous board...Nyhetstjänster
